Press release

Oncopeptides selected to present additional data from OCEAN study at the American Society of Hematology meeting

November 13, 2023

Stockholm – November 13, 2023 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at the 65th annual American Society of Hematology (ASH) Meeting and Exposition. The conference takes place in San Diego between December 9-12.

ASH is the world’s largest professional hematologic society serving both clinicians and scientists around the world who are working to conquer blood diseases.

The phase 3 OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.

“This long-term follow-up of OCEAN confirms the favorable safety and overall survival outcomes of melflufen + dexametason in patients that have not progressed within 36 months after a stem cell transplantation and supports its use in patients with relapsed, refractory multiple myeloma,” says Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital. “We are happy to have been selected to present our findings at ASH and look forward to the opportunity.”

Find more details about the abstract and presentation below. The abstract including key data has been published and is available through this link.
For more information about ASH Annual Meeting and Exposition, click here.

Title Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)
Publication Number 2018
Presenting author Fredrik Schjesvold, MD, Head of Oslo Myeloma Center, Oslo University Hospital
Program Oral and Poster Abstracts
Session 653. Multiple Myeloma: Prospective Therapeutic Trials: Poster I